vs
Side-by-side financial comparison of CALLAN JMB INC. (CJMB) and Scinai Immunotherapeutics Ltd. (SCNI). Click either name above to swap in a different company.
CALLAN JMB INC. is the larger business by last-quarter revenue ($1.2M vs $773.0K, roughly 1.5× Scinai Immunotherapeutics Ltd.).
CJMB vs SCNI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $773.0K |
| Net Profit | $-2.6M | — |
| Gross Margin | 30.3% | — |
| Operating Margin | -216.6% | — |
| Net Margin | -223.8% | — |
| Revenue YoY | — | 172.2% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.58 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | — | ||
| Q3 25 | $1.4M | — | ||
| Q2 25 | $1.7M | $773.0K | ||
| Q1 25 | $1.4M | — | ||
| Q2 24 | — | $284.0K |
| Q4 25 | $-2.6M | — | ||
| Q3 25 | $-2.7M | — | ||
| Q2 25 | $-1.4M | — | ||
| Q1 25 | $-1.2M | — | ||
| Q2 24 | — | — |
| Q4 25 | 30.3% | — | ||
| Q3 25 | 34.1% | — | ||
| Q2 25 | 38.6% | — | ||
| Q1 25 | 42.5% | — | ||
| Q2 24 | — | — |
| Q4 25 | -216.6% | — | ||
| Q3 25 | -129.9% | — | ||
| Q2 25 | -84.2% | — | ||
| Q1 25 | -85.4% | — | ||
| Q2 24 | — | — |
| Q4 25 | -223.8% | — | ||
| Q3 25 | -188.8% | — | ||
| Q2 25 | -83.9% | — | ||
| Q1 25 | -85.6% | — | ||
| Q2 24 | — | — |
| Q4 25 | $-0.58 | — | ||
| Q3 25 | $-0.61 | — | ||
| Q2 25 | $-0.31 | — | ||
| Q1 25 | $-0.32 | — | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.1M | $989.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3M | $7.9M |
| Total Assets | $5.8M | $11.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | — | ||
| Q3 25 | $2.8M | — | ||
| Q2 25 | $4.2M | $989.0K | ||
| Q1 25 | $5.2M | — | ||
| Q2 24 | — | $3.1M |
| Q4 25 | $2.3M | — | ||
| Q3 25 | $4.2M | — | ||
| Q2 25 | $5.8M | $7.9M | ||
| Q1 25 | $6.8M | — | ||
| Q2 24 | — | $-7.3M |
| Q4 25 | $5.8M | — | ||
| Q3 25 | $7.7M | — | ||
| Q2 25 | $9.0M | $11.8M | ||
| Q1 25 | $8.5M | — | ||
| Q2 24 | — | $14.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-659.0K | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-659.0K | — | ||
| Q3 25 | $-1.8M | — | ||
| Q2 25 | $-563.3K | — | ||
| Q1 25 | $-1.6M | — | ||
| Q2 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | $-1.9M | — | ||
| Q2 25 | $-995.8K | — | ||
| Q1 25 | $-1.6M | — | ||
| Q2 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -133.5% | — | ||
| Q2 25 | -59.8% | — | ||
| Q1 25 | -108.8% | — | ||
| Q2 24 | — | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 26.0% | — | ||
| Q1 25 | 1.0% | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CJMB
| Governmental | $1.1M | 91% |
| Other | $106.5K | 9% |
SCNI
Segment breakdown not available.
